Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Definately Not Bankruptcy !!!

<< Previous

Bullboard Posts

Next >>

Comment by SeeDonRunon Oct 02, 2021 9:51pm

116 Views

Post# 33958152

RE:Re: Definately Not Bankruptcy !!!

HighSkies2019 wrote: Well they would hold the shares i would think for a bit to see how clinical trials perform and or price action ...and that at least would give all investors better insight to make better decisions of their own position ....so definately not bankruptcy

Can't go bankrupt unless you owe a lot of money. Clas owes squat so, as long as there is a phone number and an address of an office of some kind and some shmuck is paying the fees to stay registered it can last forever doing what it does best - nothing.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects